Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment
PBPK models for genistein and daidzein were developed as a central component of an NGRA read-across case study. This will help to gain regulatory confidence in the use of PBPK models, especially for cosmetic ingredients.
Authors
- Camille Géniès (ORCID: https://orcid.org/0000-0003-3535-4530)
- Nicola J. Hewitt (ORCID: https://orcid.org/0000-0002-1045-0748)
- Abdulkarim Najjar (ORCID: https://orcid.org/0000-0003-4620-9830)
- Eric Fabian (ORCID: https://orcid.org/0009-0001-7592-5580)
- Carine Jacques (ORCID: https://orcid.org/0000-0001-6839-6417)
- Jochen Kuehnl
- Andreas Schepky
- Anne Zifle
- Daniela Lange
Institutions
- Beiersdorf (Germany) (DE)
- Kao Corporation (Germany) (DE)
- BASF (Germany) (DE)
- Cosmetics Europe (BE)
- Pierre Fabre (France) (FR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-03
- DOI
- https://doi.org/10.3389/fphar.2024.1421650
- Citations
- 8
- Primary Topic
- Phytoestrogen effects and research
- Type
- article
- Field-Weighted Citation Impact
- 3.40